Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study.
Journal of Alzheimer's disease reports
BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia, accounting for 80% of all cases. Mild cognitive impairment (MCI) is a transitional state between normal aging and AD. Early detection is crucial, as irreversible brain damage occurs before symptoms manifest.
OBJECTIVE: This study aimed to identify potential biomarkers for early detection of AD by analyzing urinary cytokine concentrations. We investigated 37 cytokines in AD, MCI, and cognitively normal individuals (NC), assessing their associations with AD development.
METHODS: Urinary cytokine concentrations were measured in AD (
RESULTS: Significant perturbations in IL6ST and MMP-2 concentrations were observed in AD urine compared to NC, suggesting their potential as biomarkers. TNFRSF8, IL6ST, and IL-19 differed significantly between AD and MCI, implicating them in disease progression. Diagnostic models exhibited promising performance (AUC: 0.59-0.79, sensitivity: 0.72-0.80, specificity: 0.56-0.78) in distinguishing AD from NC. In-silico analysis revealed molecular insights, including relevant non-coding RNAs, microRNAs, and transcription factors.
CONCLUSION: This study establishes significant associations between urinary cytokine concentrations and AD and MCI. IL6ST, MMP-2, TNFRSF8, IL6ST, and IL-19 emerge as potential biomarkers for early detection of AD. In-silico analysis enhances understanding of molecular mechanisms in AD. Further validation and exploration of these biomarkers in larger cohorts are warranted to assess their clinical utility.
Saiyed N, Yilmaz A, Vishweswariah S, Maiti AK, Ustun I, Bartolone S, et al [Osentoski T, Ruff S, Pai A, Maddens M, Imam K, Graham SF] Urinary cytokines as potential biomarkers of mild cognitive impairment and alzheimer's disease: a pilot study. J Alzheimers Dis Rep. 2023 Jun 27;7(1):649-657. doi: 10.3233/ADR-220081. PMID: 37483327.